

## Emyria Receives Firm Bids of \$2.525M in Strongly Supported Placement

### HIGHLIGHTS

Firm bids received from new and existing sophisticated and professional investors for a placement of \$2.525M (before costs) at \$0.035 per share ("Placement")

Chairman Greg Hutchinson provided a significant cornerstone, subscribing for \$1,000,000 (subject to shareholder approval)

Funds to support expansion of mental health treatment services at Emyria's Empax Centre - including a recently approved treatment-resistant depression program

Emyria is actively engaged with major health funds to explore sustainable funding for its programs

**Emyria Limited (ASX: EMD)** "Emyria", or the "Company") developing and delivering new treatments for mental health and select neurological conditions, has accepted firm bids of \$2.525M (before costs) from new and existing sophisticated investors.

### Use of Proceeds

Funds raised will support the continued expansion of Emyria's bespoke treatment programs for major unmet mental health needs. These include Emyria's Post-Traumatic Stress Disorder ('PTSD') program, which is already delivering industry leading results <sup>1</sup>, and the Company's newly approved program for treatment-resistant depression.<sup>2</sup>

PTSD and treatment-resistant depression represent large, unmet needs affecting over 1,000,000 Australians collectively.<sup>3</sup> With world-class facilities and unique care programs - backed by an experienced clinical team- as well as active engagement from a number of large health payers, Emyria is uniquely positioned to scale its model to further improve patient access and wellbeing.<sup>3</sup>

*"Australia's mental health crisis is escalating rapidly, underscoring the urgent need for more effective solutions.*

*As a leader in world-class mental health programs, Emyria is uniquely positioned, and obligated, to address this challenge.*

*As the only ASX-listed company delivering direct care in this field, our mission is clear: to expand access to our innovative treatments, improving the lives of more Australians."* - **Greg Hutchinson, Chairman**





### Details of the Placement:

The Placement comprises the issue of approximately 72,142,858 fully paid ordinary shares at \$0.035 each ("Placement Shares") representing a 10.26% discount to the last traded price as at 22 November 2024. Or a 3.13% discount to the 15-day volume-weighted average price ('VWAP').

The Placement Shares will be issued in two tranches. The first tranche of approximately 43,571,429 Placement Shares will be issued pursuant to the Company's available placement capacity under ASX Listing Rule 7.1 and will raise \$1.525M (before costs). Chairman, Greg Hutchinson, provided a cornerstone investment of \$1,000,000. The second tranche of approximately 28,571,429 Placement Shares to be issued to Chairman Greg Hutchinson (or nominee) to raise \$1,000,000 will be issued subject to shareholder approval to be sought at a General Meeting of shareholders expected to be held in February 2025.

62 Capital Pty Ltd ("62 Capital") served as Lead Manager for the Placement and has elected to receive its 6% capital raising fee for funds directly raised under the Placement in fully paid ordinary shares, issued at the Placement price of \$0.035 each. This equates to 1,628,571 shares, which will be issued under the Company's ASX Listing Rule 7.1 placement capacity.

Settlement of the first tranche of the Placement is expected to occur on or around Monday, 9 December 2024 with the issue of the first tranche of Placement Shares expected to occur on or around Wednesday, 11 December 2024.

### References:

1. See ASX release 02 September 2024
2. See ASX release 25 November 2024
3. AIHW (Australian Institute of Health and Welfare) (2023) Australian Burden of Disease Study 2023, AIHW, Australian Government

This release has been approved by the Board of Emyria.

***For further information, investment opportunities, or more about our approach to mental health treatment, please contact:***

**Managing Director**  
**Michael Winlo**  
**+61 (0) 8 6559 2800**  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Media Contact**  
**Haley Chartres**  
**+61 (0) 423 139 163**  
[haley@hck.digital](mailto:haley@hck.digital)

**Corporate Advisor**  
**Sufian Ahmad**  
**+61 (0) 412 316 162**  
[info@62capital.com.au](mailto:info@62capital.com.au)

**Emyria Limited** develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and drug development:

generates

**Emyria Healthcare:** Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for depression.


informs

**Emyria Data:** Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

**Emyria's Pipeline:** New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

## EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

## Risks associated with the use of Psilocybin and MDMA

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects of psilocybin and MDMA are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.